17q12
Recent articles
Population study downgrades some copy number variants’ impact on autism
Some copy number variants may boost a person’s chances of having autism, but to a lesser extent than previously thought.
Population study downgrades some copy number variants’ impact on autism
Some copy number variants may boost a person’s chances of having autism, but to a lesser extent than previously thought.
From 0 to 60 in 10 years
After a decade of fast-paced discovery, researchers are racing toward bigger datasets, more genes and a deeper understanding of the biology of autism.
From 0 to 60 in 10 years
After a decade of fast-paced discovery, researchers are racing toward bigger datasets, more genes and a deeper understanding of the biology of autism.
Explore more from The Transmitter
‘Tour de force’ study flags fount of interneurons in human brain
The newly discovered cell type might point to the origins of the inhibitory imbalance linked to autism and other conditions.
‘Tour de force’ study flags fount of interneurons in human brain
The newly discovered cell type might point to the origins of the inhibitory imbalance linked to autism and other conditions.
Michael Shadlen explains how theory of mind ushers nonconscious thoughts into consciousness
All of our thoughts, mostly nonconscious, are interrogations of the world, Shadlen says. The opportunity to report our answers to ourselves or others brings a thought into conscious awareness.
Michael Shadlen explains how theory of mind ushers nonconscious thoughts into consciousness
All of our thoughts, mostly nonconscious, are interrogations of the world, Shadlen says. The opportunity to report our answers to ourselves or others brings a thought into conscious awareness.
‘Peer review is our strength’: Q&A with Walter Koroshetz, former NINDS director
In his first week off the job, the former National Institute of Neurological Disorders and Stroke director urges U.S. scientists to remain optimistic about the future of neuroscience research, even if the executive branch “may not value what we do.”
‘Peer review is our strength’: Q&A with Walter Koroshetz, former NINDS director
In his first week off the job, the former National Institute of Neurological Disorders and Stroke director urges U.S. scientists to remain optimistic about the future of neuroscience research, even if the executive branch “may not value what we do.”